Peptides DB
Research-centric peptide and protocol reference hub
Study 25 of 25Carbetocin literaturePakistan journal of medical sciences · RCT2023

Carbetocin versus oxytocin during elective cesarean delivery: A randomized double-blind trial.

Carbetocin may reduce intraoperative blood loss and the need for additional uterotonics compared to oxytocin during elective cesarean delivery.

Read at Pakistan journal of medical sciencesAdd to compare

Where it sits

this study against the rest of the carbetocin corpus
2
Preclinical
16
Observational
0
Open-label
5
Randomised · this one
2
Reviews

Summary and findings

This study compared carbetocin and oxytocin in 100 patients undergoing elective cesarean delivery, focusing on intraoperative blood loss and uterine tone. Carbetocin was administered as a 100 μg intravenous bolus, while oxytocin was given as a 0.6 IU bolus followed by a 15 IU/h infusion. The results indicated that carbetocin was associated with lower blood loss and reduced need for additional uterotonics.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Intraoperative blood loss was significantly lower in the carbetocin group than in the oxytocin group (p<0.001).n=1002023

Abstract

The authors’ words, as Pakistan journal of medical sciences supplied them

<h4>Objective</h4>Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity following cesarean delivery. This study aimed to compare the effects of carbetocin and oxytocin on intraoperative blood loss during elective cesarean delivery, with secondary evaluation of uterine tone, additional uterotonic requirements, and intraoperative hemodynamic parameters.<h4>Methodology</h4>This prospective, randomized, double-blind study was conducted at Van Yuzuncu Yil University Dursun Odabaş Medical Center between 2023 and 2024 and included 100 patients undergoing elective cesarean delivery. Patients were randomly assigned to receive either oxytocin (Group O; 0.6 IU intravenous bolus followed by a 15 IU/h infusion) or carbetocin (Group C; 100 μg administered intravenously over 30-60 seconds). Patients with major obstetric complications, placental invasion disorders, hypertensive disorders of pregnancy, significant cardiovascular or respiratory disease, or hepatic or renal dysfunction were excluded. Intraoperative blood loss, uterine tone, additional uterotonic requirements, and hemodynamic parameters were compared.<h4>Results</h4>Baseline demographic characteristics were comparable between groups (p>0.05). Intraoperative blood loss was significantly lower in the carbetocin group than in the oxytocin group (p<0.001). The need for additional uterotonic agents was significantly lower in the carbetocin group both within the first 5 minutes (2% vs. 12%) and throughout surgery (10% vs. 26%) (p<0.05 for both). Uterine tone was significantly higher in the carbetocin group at 5 minutes (p=0.016), whereas higher scores were observed in the oxytocin group at 10 minutes (p=0.034). No clinically significant differences were observed in intraoperative hemodynamic parameters.<h4>Conclusion</h4>Although carbetocin and oxytocin demonstrated comparable intraoperative hemodynamic profiles, carbetocin was associated with reduced intraoperative blood loss, improved early uterine tone, and a lower requirement for additional uterotonic agents. Its single-dose administration and favorable safety profile make it a practical and effective uterotonic option for elective cesarean delivery.

Background

This paper addresses the clinical question of how carbetocin compares to oxytocin in managing intraoperative blood loss during elective cesarean delivery. Previous studies have indicated that postpartum hemorrhage is a leading cause of maternal morbidity, highlighting the need for effective uterotonics. Understanding the comparative effectiveness of these two agents is critical for improving maternal outcomes during cesarean deliveries.

Methods

This was a prospective, randomized, double-blind study conducted at Van Yuzuncu Yil University Dursun Odabaş Medical Center with 100 patients undergoing elective cesarean delivery. Participants were randomly assigned to receive either oxytocin (0.6 IU intravenous bolus followed by a 15 IU/h infusion) or carbetocin (100 μg intravenously over 30-60 seconds). The primary outcome was intraoperative blood loss, with secondary outcomes including uterine tone, additional uterotonic requirements, and hemodynamic parameters.

Results

The primary endpoint showed that intraoperative blood loss was significantly lower in the carbetocin group than in the oxytocin group (p<0.001). The need for additional uterotonics was lower in the carbetocin group at both 5 minutes (2% vs. 12%, p<0.05) and throughout surgery (10% vs. 26%, p<0.05). Uterine tone was significantly higher in the carbetocin group at 5 minutes (p=0.016), while the oxytocin group had higher scores at 10 minutes (p=0.034). No clinically significant differences were noted in hemodynamic parameters.

Interpretation

The findings suggest that carbetocin may be more effective than oxytocin in reducing intraoperative blood loss and the need for additional uterotonics during elective cesarean deliveries. However, while the statistical significance is clear, the clinical significance of these findings should be carefully considered, especially given the study's limitations such as a single-site design and exclusion criteria. These results may inform practice but should be interpreted with caution.

Key findings

  • Intraoperative blood loss was significantly lower in the carbetocin group than in the oxytocin group (p<0.001).
  • The need for additional uterotonic agents was significantly lower in the carbetocin group within the first 5 minutes (2% vs. 12%, p<0.05).
  • The need for additional uterotonic agents was significantly lower in the carbetocin group throughout surgery (10% vs. 26%, p<0.05).
  • Uterine tone was significantly higher in the carbetocin group at 5 minutes (p=0.016).
  • Higher uterine tone scores were observed in the oxytocin group at 10 minutes (p=0.034).
  • No clinically significant differences were observed in intraoperative hemodynamic parameters.

Limitations

  • Single-site study may limit generalizability.
  • Exclusion of patients with major obstetric complications.
  • Short follow-up period.
  • No long-term outcomes reported.

Elsewhere in the Carbetocin corpus

BGraded Epidural Anaesthesia for Caesarean Section in the Presence of an Untreated Spetzler-Martin Grade V Cerebral Arteriovenous Malformation With Radiological Progression Over Six Years: A Case Report.Cureus · 2023 · n=1 · Not reported in abstract.HumanBRetrospective cost-effectiveness analysis of carbetocin for the prevention of postpartum hemorrhage after vaginal birth: Evidence from a tertiary maternity center in France.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2024 · n=1404 · Severe PPH (≥1000 mL) occurred in 1.3% with carbetocin vs. 3.0% with oxytocin, P=0.0244.HumanAThe Effect of Carbetocin on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled QT/QTc Study in Healthy Adults.Clinical and translational science · 2023 · n=42 · Estimated mean placebo-corrected oQTcI change from baseline was 4.5 msec (90% CI: 3.4, 5.6).HumanATiming of carbetocin administration in vaginal deliveries: a double-blind, randomized controlled trial.Journal of perinatal medicine · 2025 · n=160 · Incidence of PPH was significantly lower in the carbetocin-before group than in the carbetocin-after group (p=0.015).HumanCAdministering carbetocin before electroejaculation in bulls improves semen quality and increases the number of insemination doses.Animal reproduction science · 2026 · n=29 · Slightly enhanced semen mass motility (P = 0.05).AnimalBReplacing Routine Oxytocin Infusion With Single-Dose Carbetocin at Elective Caesarean Section: A Service Improvement Evaluation of Postpartum Haemorrhage Outcomes.Cureus · 2024 · n=838 · Significant postpartum haemorrhage rates of 2.55% in the oxytocin cohort and 2.69% in the carbetocin cohort.Human